Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$51.65−1.52 (-2.86%)
Close on Nov 17, 2026Market cap $7.18BP/E –Yield –
Cytokinetics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Cytokinetics's total debt was $275.56M at Jun 30, 2026. For fiscal 2025 it was $287.57M, up 174.5% from the year before. Over ten years it grew 34.7% a year on average. The highest annual figure on record is $287.57M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $287.57M | +174.5% |
| FY2024 | Dec 31, 2024 | $104.75M | +53.0% |
| FY2023 | Dec 31, 2023 | $68.46M | +5.7% |
| FY2022 | Dec 31, 2022 | $64.77M | +36.7% |
| FY2021 | Dec 31, 2021 | $47.37M | +2.5% |
| FY2020 | Dec 31, 2020 | $46.21M | +2.6% |
| FY2019 | Dec 31, 2019 | $45.05M | +6.2% |
| FY2018 | Dec 31, 2018 | $42.41M | +33.5% |
| FY2017 | Dec 31, 2017 | $31.78M | +6.3% |
| FY2016 | Dec 31, 2016 | $29.88M | +104.1% |
| FY2015 | Dec 31, 2015 | $14.64M | – |
| FY2014 | Dec 31, 2014 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $275.56M | +58.9% |
| Q1 FY2026 | Mar 31, 2026 | $292.02M | +178.2% |
| Q4 FY2025 | Dec 31, 2025 | $287.57M | +174.5% |
| Q3 FY2025 | Sep 30, 2025 | $176.03M | +68.4% |
| Q2 FY2025 | Jun 30, 2025 | $173.46M | +66.2% |
| Q1 FY2025 | Mar 31, 2025 | $104.99M | +53.6% |
| Q4 FY2024 | Dec 31, 2024 | $104.75M | +53.0% |
| Q3 FY2024 | Sep 30, 2024 | $104.54M | +71.7% |
| Q2 FY2024 | Jun 30, 2024 | $104.35M | +67.0% |
| Q1 FY2024 | Mar 31, 2024 | $68.34M | +6.6% |
| Q4 FY2023 | Dec 31, 2023 | $68.46M | +5.7% |
| Q3 FY2023 | Sep 30, 2023 | $60.89M | -4.2% |
| Q2 FY2023 | Jun 30, 2023 | $62.49M | +0.2% |
| Q1 FY2023 | Mar 31, 2023 | $64.11M | +4.8% |
| Q4 FY2022 | Dec 31, 2022 | $64.77M | +36.7% |
| Q3 FY2022 | Sep 30, 2022 | $63.54M | +35.0% |
| Q2 FY2022 | Jun 30, 2022 | $62.34M | +33.2% |
| Q1 FY2022 | Mar 31, 2022 | $61.17M | +31.5% |
| Q4 FY2021 | Dec 31, 2021 | $47.37M | +2.5% |
| Q3 FY2021 | Sep 30, 2021 | $47.08M | +2.5% |
| Q2 FY2021 | Jun 30, 2021 | $46.79M | +2.5% |
| Q1 FY2021 | Mar 31, 2021 | $46.50M | +2.6% |
| Q4 FY2020 | Dec 31, 2020 | $46.21M | +2.6% |
| Q3 FY2020 | Sep 30, 2020 | $45.92M | +2.6% |
| Q2 FY2020 | Jun 30, 2020 | $45.63M | +2.6% |
| Q1 FY2020 | Mar 31, 2020 | $45.34M | +6.4% |
| Q4 FY2019 | Dec 31, 2019 | $45.05M | +6.2% |
| Q3 FY2019 | Sep 30, 2019 | $44.76M | +6.8% |
| Q2 FY2019 | Jun 30, 2019 | $44.47M | +37.4% |
| Q1 FY2019 | Mar 31, 2019 | $42.59M | +33.3% |
| Q4 FY2018 | Dec 31, 2018 | $42.41M | +33.5% |
| Q3 FY2018 | Sep 30, 2018 | $41.91M | +38.3% |
| Q2 FY2018 | Jun 30, 2018 | $32.37M | +7.3% |
| Q1 FY2018 | Mar 31, 2018 | $31.95M | +6.4% |
| Q4 FY2017 | Dec 31, 2017 | $31.78M | +6.3% |
| Q3 FY2017 | Sep 30, 2017 | $30.30M | +1.9% |
| Q2 FY2017 | Jun 30, 2017 | $30.16M | – |
| Q1 FY2017 | Mar 31, 2017 | $30.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $29.88M | – |
| Q3 FY2016 | Sep 30, 2016 | $29.74M | – |
See a number that looks wrong?